Friday, April 5, 2019

Canadian Advertising and Promotion Regulations Really Are As Strict As We Thought

I was fortunate to spend a couple of days last week in Vancouver, B.C. attending an American Bar Association Business Law Section meeting, where I joined a panel to discuss the myriad intellectual property (“IP”) issues business lawyers advising cannabis clients should be thinking about. The panel was comprised of both Canadian and U.S. attorneys, and we sought to provide a comparison of the IP issues faced by U.S. and Canadian cannabis companies.

Of course, the two industries are becoming increasingly more intertwined, as companies from both countries seek to expand into the other, and as investments are moving across the border with regularity. I’ve written previously about many of my U.S. clients who are licensing their brands (and providing other advisory services) to Canadian companies, as well as the difficulties posed by the Canadian cannabis regulations which went into effect last October.

canada cannabis advertising

There are many restrictions placed on how cannabis brands can be marketed via the cannabis regulatory framework. For example, cannabis trademarks may not be used to promote cannabis goods:

  • In a manner that appeals to children;
  • By means of a testimonial or endorsement;
  • By depicting a person, character or animal, whether real or fictional;
  • By presenting the product or brand elements in a manner that evokes a positive or negative emotion about or image of, a way of life such as one that includes glamour, recreation, excitement, vitality, risk, or daring;
  • By using information that is false, misleading or deceptive, or that is likely to create an erroneous impression about the product’s characteristics, value, quantity, composition, strength, concentration, potency, purity, quality, merit, safety, health effects or health risks;
  • By using or displaying a brand element or names of persons authorized to produce, sell or distribute cannabis in connection with the sponsorship of a person, entity, event, activity or facility, or on a facility used for sports, or a cultural event or activity; and
  • By communicating information about price and distribution (except at point of sale).

Given how limiting these regulations are, many Canadian companies were waiting to see how and if Health Canada would go about enforcing them. Many companies thought the rules wouldn’t be strictly enforced and have been engaging in extensive promotion of their brands that is arguably in violation of the rules.

However, on March 8th, 2019, Health Canada issued a letter to license holders that essentially told licensees that the government sees what they’re doing, it violates the rules, and if they don’t cut it out, enforcement will ensue. Below is an excerpt from that letter, addressed to all license holders:

Following the coming into force of the Cannabis Act (the Act) on October 17, 2018, Health Canada has noted some promotional activities, including online content, that may not be compliant with the promotion prohibitions prescribed in the Act. This letter is to remind license holders of their obligation to comply with the Act, including the prohibitions relating to the promotion of cannabis, cannabis accessories and services related to cannabis, as well as prohibitions relating to the packaging and labeling of cannabis and cannabis accessories.

Since the Act has come into force, Health Canada has observed the following activities which may contravene the prohibitions relating to promotion, packaging and labeling:

  • Promotions and product packaging and labeling that contain references to product names which could be appealing to young persons, or that depict, through the use of written words or pictures, a person, character, or animal; and
  • Promotions and product packaging and labeling that contain associations with, or that evoke a positive or negative emotion about or image of, a way of life such as one that includes glamour, recreation, excitement, vitality, risk or daring.”

In addition, Health Canada pointed out that a good deal of online promotional content on websites and social media sites is being made available by cannabis companies without any steps being taken to ensure that the promotion cannot be accessed by young persons. This is a violation of the rules and companies must implement steps to ensure youth cannot access promotional content. In the case of many social media platforms, it is unclear what steps can or should be taken by license holders to meet this goal.

And finally, Health Canada noted that violation of these rules could result in a fine of up to $5,000,000 or imprisonment for a term of up to three years or both. This letter should serve as a warning for Canadian companies that haven’t taken these restrictions seriously, and should also serve to set the expectations of U.S. companies looking to do business in Canada, since these restrictions are more onerous than any we’ve seen at the state or local level in the U.S..



source https://www.cannalawblog.com/canadian-advertising-and-promotion-regulations-really-are-as-strict-as-we-thought/

Wednesday, April 3, 2019

FDA Enforcement Priorities for CBD Products: We Can Roll With That

FDA CBDLast week, we explored whether the addition of hemp-derived cannabidiol (CBD) to food and beverages is actually unlawful, notwithstanding FDA policy. In that article we explained that we hadn’t seen much in the way of FDA enforcement, and that we “believe that FDA will likely continue to act where people make health claims that violate the Food Drug & Cosmetic Act” and not much more. A few days later, outgoing FDA commissioner Scott Gottlieb clarified the FDA’s enforcement position in testimony to a Senate subcommittee. That clarification was essentially in line with what we had presumed. So today we can talk about that.

In his testimony, Gottlieb stated that the FDA has been using enforcement discretion. Specifically, Gottlieb advised that “I will take enforcement action against CBD products that are on the market if manufacturers are making what I consider over-the-line claims”; for example, that CBD can “cure cancer or prevent Alzheimer’s disease.” Gottlieb continued:

But there are products on the market right now that, given our enforcement priorities and our limited resources, we haven’t taken action against. That’s not an invitation for people to continue marketing these products—we’re concerned about it—but we heard Congress loud and clear here.”

The products Gottlieb is talking about are seemingly everywhere these days, from farmer’s markets to big box retail stores. Every week, we receive scores of inquiries from current and potential manufacturers, distributors and retailers of these products. They are everywhere. In his testimony on enforcement priorities, Gottlieb acknowledged that Congress intended to legalize industrial hemp and its derivatives via the 2018 Farm Bill. It’s also fair to say, though, that Congress didn’t give much consideration to the effects (or non-effects) the Farm Bill would have on the FDA’s CBD position.

In any case, FDA is focused on the “problem” actors given its limited resources. Problem actors are the people who advertise medical solutions that entice consumers to forego approved treatment, and who generally mislead the public. As we wrote last week, FDA’s concern there is nothing new: it has always been vigilant about unapproved medical claims. (The agency fired off another round of warning letters last Thursday.)

What else can we glean from Gottlieb’s testimony? A couple of things. The first is that the situation with CBD in foods and beverages (and cosmetics, and everything else) is about as legally cumbersome as could be. It has put FDA in a bind. The second is that everyone wants answers, including Congress, which probably should have addressed this in the Farm Bill or in companion legislation. And the third is that FDA’s position could change fast. Gottlieb’s testimony was, for all intents and purposes, an exit interview. Not only is Gottlieb departing, but the agency has since announced public hearings on CBD products next month, along with a work group “explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed.”

We wrote last week that FDA appears to be moving toward solutions for hemp-CBD in the marketplace, rather than in the opposite direction. People in the market today with products that 1) are responsibly sourced and 2) do not make health claims, have a big head start. Time will tell if those propositions pay off, but they look pretty good right now — at least from an FDA enforcement perspective.



source https://www.cannalawblog.com/fda-enforcement-priorities-for-cbd-products-we-can-roll-with-that/

Tuesday, April 2, 2019

BREAKING NEWS: FDA Issues More Guidance on CBD Products

CBD FDA

On April 2, 2019, the federal Food & Drug Administration (“FDA”) Commissioner Scott Gottlieb issued a press release on hemp and hemp-derived cannabidiol (“Hemp CBD”). This is Gottlieb’s first major official press release since the now infamous December 20, 2018 press release which came just hours after the 2018 Farm Bill passed. In that December 20 press release, the FDA stated that even though the 2018 Farm Bill removed hemp from the Controlled Substances Act, the FDA still retained authority over Hemp CBD additives to foods (both human and animal), drugs, and dietary supplements.

Since the 2018 Farm Bill passed and the FDA issued the December 20 press release, there has been a proliferation of various Hemp CBD products nationwide and only very little FDA enforcement. During this time, the FDA has apparently been scrambling to figure out what to do about Hemp CBD (which you can read about here and here).

In today’s press release, the FDA gave some more guidance on what exactly it was doing:

  1. The FDA will be holding a public hearing on May 31, 2019 to get input from the public so that it can use that information in regulating the Hemp CBD;
  2. The FDA is creating a “working group” to “explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed.”
  3. The FDA issued three more warning letters to operators whom it believes have made medical statements concerning Hemp CBD products that were “egregious”.

Another key aspect of the FDA’s guidance is its updated FAQs. In the FAQs (see number 13), the FDA responds to questions regarding cosmetics (which can include things such as topicals) as follows:

If a product is intended to affect the structure or function of the body, or to diagnose, cure, mitigate, treat or prevent disease, it is a drug, or possibly both a cosmetic and a drug, even if it affects the appearance. (See Question #3 for more information about drugs.)

FDA can take action if it has information that an ingredient or cosmetic product is unsafe to consumers. Consumers can report adverse events associated with cosmetic products via the FDA’s MedWatch reporting system, either online or by phone at 1-800-FDA-1088, or by contacting your nearest FDA district office consumer complaint coordinator. For more information, please see the FDA’s webpage on how to report a cosmetic-related complaint.

This is an interesting response and we will be sure to give more insight on it in the coming days. But suffice it to say, the FDA apparently isn’t taking as hard a stance against cosmetics as it is against foods. It appears (at least for now) that the FDA is poised to send warning letters to companies selling Hemp CBD topicals IF those topicals are marketed in a way that makes them “drugs”.

Stay tuned to the Canna Law Blog for more on the FDA’s position on Hemp CBD.



source https://www.cannalawblog.com/breaking-news-fda-issues-more-guidance-on-cbd-products/

Cannabis Litigation: Another Federal Court RICO Case Dismissal

rico cannabis litigation

Last week the federal district court in Oregon dismissed with prejudice the plaintiffs’ amended complaint in Ainsworth v. Owenby, Case 6:17-cv-1935. As you may recall, this is one of several cases tracked by this blog in which a group of residential property owners displeased with alleged deleterious effects of a marijuana production or processing facility on nearby land seek relief in a civil RICO action. We have discussed Ainsworth here and here.

The original complaint was filed in late 2017 and alleged one state-law nuisance claim and two RICO claims. In a prior post we discussed the similarities and differences between Ainsworth and another civil RICO case in Oregon, McCart, which appeared to have resolved through a confidential settlement. We noted that the Ainsworth complaint appeared to have learned some valuable lessons from the motions to dismiss in McCart. Ultimately, however, whatever lessons learned were not enough to meet the onerous requirements for a civil RICO claim.

First, let’s set the stage for the recent order. In August 2018 the district court dismissed the plaintiffs’ RICO claims without prejudice, thereby giving them the opportunity to amend. That dismissal turned on the plaintiffs’ failure to plausibly allege a tangible property loss, with the court reasoning that “a plaintiff who has not alleged specific prior attempts to monetize a property interest must plausibly allege at least a present intent or desire to do so.” The court found plaintiffs’ reliance on the abstract harm of a reduction in fair market values insufficient to satisfy RICO. The plaintiffs must, said the court, make good faith allegations that they attempted or currently desire to convert those interests into a pecuniary form.

The plaintiffs then set about amending their complaint to address the shortcomings identified by the court. With respect to RICO, two of the plaintiffs now alleged that the grow operation depressed the value of their property and, as a direct result, prevented them from obtaining a larger home equity loan to finance the construction of a perimeter fence. The defendants again moved to dismiss, contending these plaintiffs still failed to allege a concrete loss as required by RICO.

The question then was whether the plaintiffs’ inability to obtain a larger home equity loan transformed their otherwise intangible injury into one resulting in concrete loss.

On March 27, 2019, the court answered that question in the negative. The key reason was that the plaintiffs’ financial position was no worse than it would have been absent the alleged racketeering activity—since the plaintiffs incurred less debt and, presumably, paid less interest based on the smaller principal. In other words, plaintiffs were in a better position than they otherwise would have been. Could the plaintiffs have potentially pleaded concrete financial harm? The court gives some hints – noting that plaintiffs did not allege they were charged a higher interest rate or otherwise offered the loan on less favorable terms, such that they were in a worse financial position.

Although Ainsworth is out of federal court absent a successful appeal, the recent order does not necessarily end litigation. That’s because the court declined to exercise supplemental jurisdiction over the state-law claims for nuisance and intentional infliction of emotional distress.  Absent a successful appeal, however, plaintiffs can no longer hold RICO’s threat of treble damages and attorneys’ fees over these Oregon cannabis producers.

For more on RICO cannabis litigation, check out the following posts:



source https://www.cannalawblog.com/cannabis-litigation-another-federal-court-rico-case-dismissal/

Monday, April 1, 2019

The Marijuana Banking Act Is Going Down (To the Floor)

marijuana banking cannabisAfter its introduction on Tuesday, March 26, 2019, the House Financial Services Committee has voted 45-15 to advance the SAFE Banking Act of 2019 to the House floor on a to-be-determined date. Currently, the Safe Banking Act has 152 cosponsors, including 12 Republicans, which is more than one-third of the entire House of Representatives. House Rules Committee Chairman James McGovern (D-MA) is hopeful that the chamber will vote on and pass the legislation within weeks.

We will guide it to the House floor for a vote, which I think it will pass with an overwhelming vote – Democrats and I think a lot of Republicans as well. If we have a strong bipartisan vote that will increase the pressure on the Senate to do something.”

Of course, much of the focus was on the “public safety concern for legitimate businesses that currently have no recourse but to operate with just cash,” as Chairwoman Maxine Waters (D-CA) indicated on Tuesday. However, Chairwoman Waters and several other Democratic supporters framed the legislation as “part of a holistic approach toward providing criminal justice reform” that “should not by any means be the only bill the House takes up on the important issue of cannabis reform.” Conversely, Rep. Patrick McHenry (R-NC), the House Financial Services Committee’s top Republican, urged in his opening remarks that the Committee “ensure that we’re doing our due diligence before proceeding” and acknowledge that “it is a massive change in federal policy.” The vote occurred on Thursday morning following two days of proceedings and over GOP objections.

Several amendments were proposed, considered, and even passed during the Committee markup. The following were most notable:

  • Additions requiring the federal government to study diversity and inclusion in the marijuana industry: this would require federal regulators to conduct studies and provide annual reports “tracking information and data on the availability of access ot financial services for minority-owned and women-owned cannabis-related legitimate businesses” (Rep. Ed Perlmutter (D-CO));
  • Additions requiring the Government Accountability Office to study banks’ previous reports on their marijuana business customers to understand how effective they are in identifying bad actors, passed via voice vote (Rep. Scott Tipton (R-CO));
  • Extension of protections to “de novo” banking institutions that seek charters or master accounts from a Federal Reserve bank, passed via voice vote (Rep. Katie Porter (D-CA));
  • Expansion of protections to insurance companies, passed via voice vote (Rep. Steve Stivers (R-OH));
  • Delay of the bill’s effective date until marijuana is federally descheduled, withdrawn (Rep. Bill Huizenga (R-MI));
  • Delay of the bill’s enactment until federal regulators are able to issue guidance to banks, defeated via voice vote and roll call vote 35-25 (Rep. Bill Huizenga (R-MI));
  • Limitation of the bill to only protect hemp businesses, defeated via voice vote and roll call vote 42-18 (Rep. Andy Barr (R-KY));
  • Withdrawal of protections from banks that serve marijuana businesses located within 1,000 feet of schools, youth centers, public parks, child care facilities, public housing, civic centers or designated drug-free zones, defeated via voice vote and roll call vote 34-26 (Rep. Sean Duffy (R-WI)).

It is expected that Senators Jeff Merkley (D-OR) and Cory Gardner (R-CO) will file companion legislation to the SAFE Banking Act in the Senate soon. The former iteration gained 20 cosponsors in the chamber but did not receive a hearing or vote. Only time will tell if cannabis banking will get a vote in the Senate, but the pressure continues to build. If nothing else, the passage of cannabis banking legislation by the House would be a truly historic marker in the march to end prohibition.



source https://www.cannalawblog.com/the-marijuana-banking-act-is-going-down-to-the-floor/

Sunday, March 31, 2019

California Cannabis Deliveries May Soon Change, Again

california cannabis delivery

For a few moments there, it seemed like the California cannabis delivery companies could deliver anywhere in the state—even to cities that said no. It now looks like that may not be allowed.

In January 2019, the California Bureau of Cannabis Control (“BCC”)—which regulates cannabis delivery companies—issued Rule 5416(d), which says that “A delivery employee may deliver to any jurisdiction within the State of California provided that such delivery is conducted in compliance with all delivery provisions of this division.” In plain English, this rule clearly allows licensed retailers to deliver cannabis to any jurisdiction in the state—even ones that didn’t allow it. This rule immediately drew the ire of cities across the state.

I’ve been writing about this rule since it was first proposed back in October 2018. In a post just after the rule was passed, I wrote that we expected litigation to ensue over this rule. Many—if not most—of the cities in the state either ban or heavily restrict cannabis operators, and many of them vocally opposed this rule in the rulemaking period. In spite of their opposition, the BCC still passed the rule. This is probably the best example of the BCC siding with the industry over municipalities, but was destined to cause a stir.

As of mid-February, it looks like at least one city was poised to sue the BCC. The City of Sonora, one of many anti-delivery cities, announced that it would file a lawsuit. If that lawsuit proceeds, however, it will be a while before there’s a final resolution unless there is some early injunction motion to hold off implementation of the rule, as litigation can take years to be resolved.

There may be another, faster way in which deliveries will be banned—state legislation. California Assembly Bill 1530 (“AB-1530”) would amend existing state law to state: “A local jurisdiction may adopt an ordinance or resolution pursuant to Section 26200 that permits, restricts, limits, or bans the delivery of cannabis or cannabis products to a location within its jurisdictional boundaries.”

If AB-1530 is passed, it will put an end to the issue. The rule would be a major disruption for cannabis delivery companies who invested heavily in a multi-city delivery business model. Some delivery licensees are permitted in small cities surrounded by numerous cities that don’t allow delivery, and if the new law is passed, it could spell major trouble for these operators.

The bill is still in its relative infancy and there may still be public hearings on it in the future. To be clear, just because the bill is up for consideration doesn’t mean it’s going to be passed. So it’s important for anyone in support of statewide delivery to oppose the legislation.



source https://www.cannalawblog.com/california-cannabis-deliveries-may-soon-change-again/